Clinical Trial Update: Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer [NA]

View source ↗

Summary

Clinical trial evaluating apricoxib, a selective COX-2 inhibitor, for modulating regulatory T cells in patients with early-stage non-small cell lung cancer; tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apricoxib (apricoxib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Non Small Cell Lung Cancer | NA | Status: TERMINATED | Results posted: 2016-02-11